Quest Diagnostics Sells Drug Royalties | Chemical & Engineering News
Volume 91 Issue 30 | p. 19 | Concentrates
Issue Date: July 29, 2013

Quest Diagnostics Sells Drug Royalties

Department: Business
Keywords: oncology, diagnostics, royalties

Quest Diagnostics has sold the rights to royalties on future sales of the anticancer drug candidate ibrutinib to Royalty Pharma for $485 million. Quest got rights to royalties on several drug candidates via its 2011 purchase of Celera. Ibrutinib development partners Johnson & Johnson and Pharmacyclics have filed for approval of the compound, which FDA has designated a breakthrough therapy. Since November 2012, Quest has been refocusing on its core diagnostics business. It earlier sold a dental diagnostics company, OralDNA, and a point-of-care testing firm, HemoCue.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment